All Stories

  1. Challenges in diagnosis of sarcoidosis
  2. Sarcoidosis: A State-Of-The-Art Review
  3. Design of a Phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
  4. Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
  5. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
  6. Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis
  7. Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
  8. The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
  9. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  10. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis
  11. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
  12. Kidney manifestations of sarcoidosis
  13. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
  14. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner
  15. Pulmonale Alveolarproteinose (PAP)
  16. Pulmonale alveoläre Mikrolithiasis (PAM)
  17. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
  18. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
  19. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  20. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  21. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  22. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  23. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  24. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  25. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  26. Genetic testing in interstitial lung disease: An international survey
  27. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  28. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  29. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  30. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  31. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  32. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  33. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  34. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  35. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  36. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  37. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  38. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  39. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  40. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  41. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  42. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  43. When the Game Changes
  44. Hypersensitivity pneumonitis
  45. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  46. Looking into the future of sarcoidosis: what is next for treatment?
  47. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  48. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  49. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  50. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  51. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  52. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  53. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  54. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  55. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  56. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  57. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  58. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  59. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  60. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  61. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  62. Shaping the future of an ultra-rare disease
  63. Editorial introductions
  64. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  65. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  66. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  67. Pulmonary alveolar proteinosis
  68. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  69. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  70. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  71. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  72. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  73. Differenzialdiagnose interstitieller Lungenerkrankungen
  74. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  75. The Management of Patients With Idiopathic Pulmonary Fibrosis
  76. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  77. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  78. Patients with IPF and lung cancer: diagnosis and management
  79. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  80. Phenotypes of organ involvement in sarcoidosis
  81. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  82. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  83. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  84. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  85. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  86. Therapeutic targets in idiopathic pulmonary fibrosis
  87. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  88. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  89. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  90. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  91. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  92. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  93. Coagulation factor XII regulates inflammatory responses in human lungs
  94. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  95. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  96. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  97. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  98. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  99. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  100. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  101. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  102. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  103. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  104. How to handle IPF – the new Portuguese consensus document
  105. An Important Step Forward, but Still a Way to Go
  106. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  107. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  108. Pulmonary alveolar proteinosis in a cat
  109. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  110. Pulmonale Alveolarproteinose
  111. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  112. New guideline on treatment of idiopathic pulmonary fibrosis
  113. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  114. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  115. Facts and promises on lung biomarkers in interstitial lung diseases
  116. Diagnosis of Sarcoidosis
  117. Update on therapeutic management of idiopathic pulmonary fibrosis
  118. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  119. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  120. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  121. Alveolar and intraparenchymal proteasome in sarcoidosis
  122. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  123. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  124. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  125. Interstitial lung disease
  126. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  127. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  128. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  129. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  130. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  131. Sarkoidose
  132. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  133. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  134. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  135. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  136. Hypersensitivity Pneumonitis
  137. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  138. Chronic Hypersensitivity Pneumonitis
  139. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  140. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  141. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  142. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  143. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  144. Therapie der Lungenfibrose
  145. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  146. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  147. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  148. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  149. Die bronchoalveoläre Lavage aus klinischer Sicht
  150. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  151. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  152. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  153. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  154. Biomarkers